Figure 2. Combined inhibition of CTNNB1 and MEK significantly improves the survival of mice bearing Ls174t liver metastases.

A, Effect of trametinib monotherapy on survival of mice bearing Ls174t liver metastases. Drug was administered p.o. at two dose levels, 3x/week as indicated by the arrows. B, Effect of combination therapy on survival of mice bearing Ls174t liver metastases. Animals were dosed i.v. with DsiRNA formulations (2 mg/kg/dose), and p.o. with trametinib (2 mg/kg/dose) on the same days, 3x weekly as indicated by the arrows (n=8/cohort). Median survival values are indicated on the figure legends. Note that, in the monotherapy experiment, the cell implantation number was lower (1 x 10⁶ cells) than in the combination experiment and in Fig 1A (2 x 10⁶ cells for both).